ACTU
Actuate Therapeutics, Inc. Common stock
Price Chart
Latest Quote
$5.03
Current Price| Previous Close | $4.71 |
| Open | $4.73 |
| Day High | $5.14 |
| Day Low | $4.62 |
| Volume | 51,001 |
Stock Information
| Shares Outstanding | 23.24M |
| Cash Equivalents | $16.92M |
| Net Income | $-24.12M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $116.91M |
| P/E Ratio | 14.79 |
| EPS (TTM) | $0.34 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 9/42| Debt to Equity | 88.44 |
| Debt to Earnings | -0.34 |
| Current Ratio | 1.05 |
| Quick Ratio | 0.98 |
| Return on Equity | -26189.05% |
| Avg FCF Growth | 7.58% |
| FCF Yield | -18.68% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $5.03 | 52,540 |
| 2026-01-30 | $4.71 | 60,900 |
| 2026-01-29 | $4.74 | 97,600 |
| 2026-01-28 | $4.97 | 117,900 |
| 2026-01-27 | $5.45 | 63,000 |
| 2026-01-26 | $5.39 | 163,700 |
| 2026-01-23 | $5.31 | 79,100 |
| 2026-01-22 | $5.45 | 87,200 |
| 2026-01-21 | $5.86 | 39,800 |
| 2026-01-20 | $5.56 | 24,500 |
| 2026-01-16 | $5.69 | 44,900 |
| 2026-01-15 | $5.32 | 58,300 |
| 2026-01-14 | $5.26 | 67,100 |
| 2026-01-13 | $5.52 | 30,200 |
| 2026-01-12 | $5.75 | 95,300 |
| 2026-01-09 | $6.14 | 71,100 |
| 2026-01-08 | $6.28 | 62,100 |
| 2026-01-07 | $6.49 | 48,300 |
| 2026-01-06 | $6.66 | 94,600 |
| 2026-01-05 | $6.34 | 326,100 |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
đ° Latest News
Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data
MT Newswires âĸ 2026-01-06T15:14:56ZActuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?
Zacks âĸ 2025-12-24T17:00:02Z
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%
Zacks âĸ 2025-11-28T14:55:03Z
Here's Why We're Watching Actuate Therapeutics' (NASDAQ:ACTU) Cash Burn Situation
Simply Wall St. âĸ 2025-11-15T12:00:06Z
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires âĸ 2025-09-10T19:52:18ZActuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20%
Simply Wall St. âĸ 2025-08-15T10:28:00Z
Actuate Therapeutics shares highlights from KOL eventon elraglusib data
TipRanks âĸ 2025-06-03T13:15:32Z
Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2025-02-12T10:55:46Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Interest Expense | $18,717 | $43,641 | $16,200 |
| Total Expenses | $25,160,734 | $24,973,829 | $20,206,807 |
| Other Income Expense | $-2,328,170 | $-79,822 | $36,579 |
| Other Non Operating Income Expenses | $-2,592,507 | - | - |
| Net Non Operating Interest Income Expense | $203,576 | $309,031 | $10,827 |
| Interest Expense Non Operating | $18,717 | $43,641 | $16,200 |
| Operating Expense | $25,160,734 | $24,973,829 | $20,206,807 |
| General And Administrative Expense | $6,484,458 | $3,265,497 | $3,819,591 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Net Interest Income | $203,576 | $309,031 | $10,827 |
| Interest Income | $222,293 | $352,672 | $27,027 |
| Normalized Income | $-27,549,665 | $-24,664,798 | $-20,195,980 |
| Net Income From Continuing And Discontinued Operation | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Total Operating Income As Reported | $-25,160,734 | $-24,973,829 | $-20,206,807 |
| Net Income Common Stockholders | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Net Income | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Net Income Including Noncontrolling Interests | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Net Income Continuous Operations | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Pretax Income | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Interest Income Non Operating | $222,293 | $352,672 | $27,027 |
| Operating Income | $-25,160,734 | $-24,973,829 | $-20,206,807 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Diluted EPS | $-3.26 | $-1.29 | $-1.34 |
| Basic EPS | $-3.26 | $-1.29 | $-1.34 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,530,948 | $-24,621,157 | $-20,179,780 |
| Total Unusual Items | $264,337 | $-79,822 | $36,579 |
| Total Unusual Items Excluding Goodwill | $264,337 | $-79,822 | $36,579 |
| EBITDA (Bullshit earnings) | $-27,266,611 | $-24,700,979 | $-20,143,201 |
| EBIT | $-27,266,611 | $-24,700,979 | $-20,143,201 |
| Diluted Average Shares | $8,372,741 | $19,111,636 | $15,033,731 |
| Basic Average Shares | $8,372,741 | $19,111,636 | $15,033,731 |
| Diluted NI Availto Com Stockholders | $-27,285,328 | $-24,744,620 | $-20,159,401 |
| Gain On Sale Of Security | $264,337 | $-79,822 | $36,579 |
| Research And Development | $18,676,276 | $21,708,332 | $16,387,216 |
| Selling General And Administration | $6,484,458 | $3,265,497 | $3,819,591 |
| Other Gand A | $2,713,565 | $1,438,247 | $1,240,369 |
| Salaries And Wages | $3,770,893 | $1,827,250 | $2,579,222 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Tangible Assets | $104,186 | $-99,626,513 | $-75,305,432 |
| Total Assets | $9,318,448 | $2,995,566 | $20,483,056 |
| Total Non Current Assets | $110,548 | $0 | $0 |
| Other Non Current Assets | $110,548 | - | - |
| Current Assets | $9,207,900 | $2,995,566 | $20,483,056 |
| Other Current Assets | $566,278 | $36,907 | $33,746 |
| Cash Cash Equivalents And Short Term Investments | $8,641,622 | $2,958,659 | $20,449,310 |
| Cash And Cash Equivalents | $8,641,622 | $2,958,659 | $20,449,310 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $9,214,262 | $102,622,079 | $95,788,488 |
| Total Non Current Liabilities Net Minority Interest | $411,759 | $95,701,485 | $91,443,506 |
| Derivative Product Liabilities | $0 | $988,049 | $814,364 |
| Tradeand Other Payables Non Current | $404,991 | $404,991 | $404,991 |
| Current Liabilities | $8,802,503 | $6,920,594 | $4,344,982 |
| Payables And Accrued Expenses | $7,914,054 | $6,643,094 | $4,212,949 |
| Interest Payable | $70,957 | $0 | - |
| Payables | $1,921,189 | $3,421,840 | $2,130,847 |
| Accounts Payable | $1,921,189 | $3,421,840 | $2,130,847 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Common Stock Equity | $104,186 | $-99,626,513 | $-75,305,432 |
| Total Equity Gross Minority Interest | $104,186 | $-99,626,513 | $-75,305,432 |
| Stockholders Equity | $104,186 | $-99,626,513 | $-75,305,432 |
| Retained Earnings | $-132,379,849 | $-105,094,521 | $-80,349,901 |
| Preferred Securities Outside Stock Equity | $0 | $94,178,404 | $90,137,751 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Ordinary Shares Number | $19,531,636 | $19,111,636 | $19,111,636 |
| Share Issued | $19,531,636 | $19,111,636 | $19,111,636 |
| Tangible Book Value | $104,186 | $-99,626,513 | $-75,305,432 |
| Invested Capital | $104,186 | $-99,626,513 | $-75,305,432 |
| Working Capital | $405,397 | $-3,925,028 | $16,138,074 |
| Total Capitalization | $104,186 | $-99,626,513 | $-75,305,432 |
| Additional Paid In Capital | $132,484,015 | $5,468,006 | $5,044,467 |
| Capital Stock | $20 | $2 | $2 |
| Common Stock | $20 | $2 | $2 |
| Preferred Stock | $0 | $0 | - |
| Non Current Accrued Expenses | $6,768 | $130,041 | $86,400 |
| Pensionand Other Post Retirement Benefit Plans Current | $888,449 | $277,500 | $132,033 |
| Current Accrued Expenses | $5,992,865 | $3,221,254 | $2,082,102 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $-21,842,648 | $-21,625,167 | $-17,794,093 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-21,842,648 | $-21,625,167 | $-17,794,093 |
| Cash Flow From Continuing Operating Activities | $-21,842,648 | $-21,625,167 | $-17,794,093 |
| Operating Gains Losses | $135,663 | $79,822 | $-36,579 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $23,956,800 | $4,134,516 | $19,255,569 |
| Financing Cash Flow | $27,525,611 | $4,134,516 | $19,255,569 |
| Cash Flow From Continuing Financing Activities | $27,525,611 | $4,134,516 | $19,255,569 |
| Net Other Financing Charges | $-1,931,189 | - | - |
| Net Preferred Stock Issuance | $0 | $4,134,516 | $19,255,569 |
| Preferred Stock Issuance | $0 | $4,134,516 | $19,255,569 |
| Net Common Stock Issuance | $23,956,800 | $0 | - |
| Common Stock Issuance | $23,956,800 | $0 | - |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Repayment Of Debt | $-200,000 | $0 | - |
| Issuance Of Debt | $5,700,000 | $0 | - |
| Interest Paid Supplemental Data | $71,033 | $0 | $0 |
| Income Tax Paid Supplemental Data | $800 | $0 | $0 |
| End Cash Position | $8,641,622 | $2,958,659 | $20,449,310 |
| Beginning Cash Position | $2,958,659 | $20,449,310 | $18,987,834 |
| Changes In Cash | $5,682,963 | $-17,490,651 | $1,461,476 |
| Net Issuance Payments Of Debt | $5,500,000 | $0 | - |
| Net Short Term Debt Issuance | $0 | $0 | - |
| Short Term Debt Payments | $-200,000 | $0 | - |
| Short Term Debt Issuance | $200,000 | $0 | - |
| Net Long Term Debt Issuance | $5,500,000 | $0 | - |
| Long Term Debt Issuance | $5,500,000 | $0 | - |
| Change In Working Capital | $1,100,076 | $2,572,451 | $1,731,621 |
| Change In Other Working Capital | $-110,548 | - | - |
| Change In Other Current Assets | $-110,548 | $0 | - |
| Change In Payables And Accrued Expense | $1,739,995 | $2,575,612 | $1,756,925 |
| Change In Accrued Expense | $3,240,646 | $1,284,619 | $1,170,666 |
| Change In Interest Payable | $-70,957 | $0 | - |
| Change In Payable | $-1,500,651 | $1,290,993 | $586,259 |
| Change In Account Payable | $-1,500,651 | $1,290,993 | $586,259 |
| Change In Prepaid Assets | $-529,371 | $-3,161 | $-25,304 |
| Other Non Cash Items | $18,641 | $43,641 | $16,200 |
| Stock Based Compensation | $1,995,793 | $423,539 | $654,066 |
| Unrealized Gain Loss On Investment Securities | $2,192,507 | $0 | - |
| Gain Loss On Investment Securities | $135,663 | $79,822 | $-36,579 |
| Net Income From Continuing Operations | $-27,285,328 | $-24,744,620 | $-20,159,401 |